Annovis Bio, Inc. (ANVS) 10-Year Financial Performance & Capital Metrics

ANVS • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

AboutAnnovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.Show more

Revenue $0
EBITDA -$27M +40.7%
Net Income -$25M +56.2%
EPS (Diluted) -2009.77 -32159.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -3159.09% -478.2%
ROIC -
Debt/Equity -
Interest Coverage -14.40

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 91 (top 9%)
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 35.6% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM39.22%

EPS CAGR

10Y-

5Y-

3Y-

TTM57.81%

ROCE

10Y Avg-184.58%

5Y Avg-184.58%

3Y Avg-222.42%

Latest-334.23%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-	-	-
Operating Expenses+	682.43K	713.94K	1.61M	6.64M	14.54M	25.51M	45.03M	26.69M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	409.06K	602.33K	829.37K	3.59M	6.06M	9M	6.24M	6.7M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	273.37K	111.61K	776.26K	3.05M	8.48M	16.52M	38.79M	20M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	378	0	0	0	0	0
Operating Income+	-682K	-714K	-1.61M	-6.64M	-14.54M	-25.51M	-45.03M	-26.69M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.05%	-1.25%	-3.13%	-1.19%	-0.75%	-0.77%	0.41%
EBITDA+	433	-63	0	0	-14.5M	-25.51M	-45.03M	-26.69M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-1.15%	1%	-	-	-0.76%	-0.77%	0.41%
D&A (Non-Cash Add-back)	682.43K	713.94K	1.61M	6.64M	0	0	0	0
EBIT	-682K	-714K	-1.61M	-6.64M	-14.5M	-25.51M	-45.03M	-26.69M
Net Interest Income+	0	0	0	-47.18M	13.34K	182.71K	667.9K	-1.52M
Interest Income	0	0	0	47.23K	13.34K	182.71K	667.9K	331.85K
Interest Expense	84	66	0	47.23M	0	0	0	1.85M
Other Income/Expense	84	66	614.64K	1.18M	50.09K	182.71K	-11.17M	2.1M
Pretax Income+	-682K	-714K	-991K	-5.46M	-14.49M	-25.33M	-56.2M	-24.59M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	0	-132	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-682K	-714K	-991K	-5.46M	-14.49M	-25.33M	-56.2M	-24.59M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	-0.05%	-0.39%	-4.51%	-1.65%	-0.75%	-1.22%	0.56%
Net Income (Continuing)	-682K	-714K	-991K	-5.46M	-14.49M	-25.33M	-56.2M	-24.59M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.16	-0.16	-0.17	-0.87	-1.90	-3.10	-6.23	-2009.77
EPS Growth %	-	0%	-0.06%	-4.12%	-1.18%	-0.63%	-1.01%	-321.6%
EPS (Basic)	-0.16	-0.16	-0.17	-0.87	-1.90	-3.10	-6.23	-2018.50
Diluted Shares Outstanding	4.39M	4.4M	6.84M	6.31M	7.63M	8.16M	9.02M	12.23M
Basic Shares Outstanding	4.39M	4.4M	6.84M	6.31M	7.63M	8.16M	9.02M	12.18M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	357.96K	50.99K	747.51K	8.12M	46M	36.02M	10.21M	13.93M
Cash & Short-Term Investments	347.47K	35.31K	1.86K	8.07M	45.69M	28.38M	5.75M	10.55M
Cash Only	347.47K	35.31K	1.86K	8.07M	45.69M	28.38M	5.75M	10.55M
Short-Term Investments	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	735.08K	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	-745.64M	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	745.65M	6.44K	9.87K	7.54M	20.8K	7.5K
Total Non-Current Assets+	0	0	369.6K	0	0	0	0	0
Property, Plant & Equipment	0	0	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	369.6K	0	0	0	0	0
Total Assets+	357.96K	50.99K	1.12M	8.12M	46M	36.02M	10.21M	13.93M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	-0.86%	20.91%	6.27%	4.67%	-0.22%	-0.72%	0.36%
Total Current Liabilities+	490.22K	567.94K	2.01M	578.38K	1.51M	7.7M	4.28M	3.88M
Accounts Payable	71.11K	68.42K	1.23M	341.86K	688.07K	3.96M	1.29M	2.31M
Days Payables Outstanding	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	415.35K	477.88K	645.34K	220.03K	105.67K	0	273	1.21M
Current Ratio	0.73x	0.09x	0.37x	14.04x	30.54x	4.68x	2.39x	3.59x
Quick Ratio	0.73x	0.09x	371.20x	14.04x	30.54x	4.68x	2.39x	3.59x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	6.83M	7.08M	7.68M	0	0	0	13.68M	737K
Long-Term Debt	0	0	499.81K	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	6.83M	7.08M	7.18M	0	0	0	13.68M	737K
Total Liabilities	7.32M	7.64M	9.69M	578.38K	1.51M	7.7M	17.96M	4.62M
Total Debt+	0	0	499.81K	0	0	0	0	0
Net Debt	-347.47K	-35.31K	497.95K	-8.07M	-45.69M	-28.38M	-5.75M	-10.55M
Debt / Equity	-	-	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-802.48x	-	-	-	-	-	-	-
Interest Coverage	-8119.05x	-10818.18x	-	-0.14x	-	-	-	-14.40x
Total Equity+	-6.97M	-7.59M	-8.58M	7.54M	44.49M	28.32M	-7.75M	9.31M
Equity Growth %	-	-0.09%	-0.13%	1.88%	4.9%	-0.36%	-1.27%	2.2%
Book Value per Share	-1.58	-1.73	-1.25	1.20	5.83	3.47	-0.86	0.76
Total Shareholders' Equity	-6.97M	-7.59M	-8.58M	7.54M	44.49M	28.32M	-7.75M	9.31M
Common Stock	0	0	0	689	810	816	1.05K	1.41K
Retained Earnings	-7.07M	-7.79M	-8.78M	-14.24M	-28.73M	-54.05M	-110.26M	-134.85M
Treasury Stock	6.73M	6.88M	0	0	0	0	0	0
Accumulated OCI	-6.83M	-7.08M	-7.08M	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-537.48K	-558.61K	-476.54K	-3.97M	-9.13M	-17.31M	-39.97M	-21.89B
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.04%	0.15%	-7.33%	-1.3%	-0.9%	-1.31%	-546.81%
Net Income	-682.35K	-713.87K	-990.98K	-5.46M	-14.49M	-25.33M	-56.2M	-24.59B
Depreciation & Amortization	0	0	1.19M	0	0	0	0	0
Stock-Based Compensation	48.49K	82.73K	8.48K	0	4.7M	9.15M	4.63M	3.84B
Deferred Taxes	0	0	-1.19M	0	0	0	0	0
Other Non-Cash Items	11.58K	85.41K	84.43K	1.89M	0	0	11.84M	-1.14B
Working Capital Changes	96.37K	72.53K	421.53K	-400.71K	657.35K	-1.14M	-228.6K	681.71K
Change in Receivables	0	0	-735.08K	735.08K	0	0	0	0
Change in Inventory	0	0	735.08K	0	0	0	0	0
Change in Payables	61.83K	-2.68K	969.09K	-695.66K	346.22K	3.27M	-2.67M	1.01M
Cash from Investing+	0	0	0	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0
Cash from Financing+	332.5K	246.45K	443.09K	12.04M	46.74M	4.61K	17.34M	26.69B
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	332.5K	246.45K	-86.91K	0	95.1K	0	458.38K	26.67B
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-537.48K	-558.61K	-476.54K	-3.97M	-9.13M	-17.31M	-39.97M	-21.89B
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	-0.04%	0.15%	-7.33%	-1.3%	-0.9%	-1.31%	-546.81%
FCF per Share	-0.12	-0.13	-0.07	-0.63	-1.20	-2.12	-4.43	-1789.51
FCF Conversion (FCF/Net Income)	0.79x	0.78x	0.48x	0.73x	0.63x	0.68x	0.71x	890.37x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-72.43%	-55.68%	-69.57%	-546.39%	-3159.09%
Interest Coverage	-8119.05x	-10818.18x	-	-0.14x	-	-	-	-14.40x
FCF Conversion	0.79x	0.78x	0.48x	0.73x	0.63x	0.68x	0.71x	890.37x

Frequently Asked Questions

Growth & Financials

Annovis Bio, Inc. (ANVS) grew revenue by 0.0% over the past year. Growth has been modest.

Annovis Bio, Inc. (ANVS) reported a net loss of $24.9M for fiscal year 2024.

Dividend & Returns

Annovis Bio, Inc. (ANVS) has a return on equity (ROE) of -3159.1%. Negative ROE indicates the company is unprofitable.

Annovis Bio, Inc. (ANVS) had negative free cash flow of $25.0M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener